Module

Advances in Targeted Therapies for the Treatment of Non-Hodgkin’s Lymphomas

Source: Advances in Lymphoproliferative Disease: From Molecular Pathogenesis to Multitargeted Treatment

Advances in Targeted Therapies for the Treatment of Non-Hodgkin’s Lymphomas

Program Chair: Alexandra M. Levine, MD

Faculty:

Andre Goy, MD, MPH

CME CREDIT INFORMATION

Release Date: 07/30/08

Expiration Date: 07/29/09

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.8 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe standard and emerging treatment options for indolent and aggressive lymphomas
Recall clinical trial data regarding the use of monoclonal antibodies in the treatment of non-Hodgkin’s lymphomas
Summarize the use of radioimmunotherapy in the treatment of lymphomas
Cite small-molecule targeted agents used to treat lymphomas

Topics covered include:

Introduction
Monoclonal Antibody Regimens for Indolent Lymphomas
Monoclonal Antibody Regimens in Aggressive Lymphomas
Proteasome Inhibition in Indolent and Aggressive Lymphomas
Radioimmunotherapy Options in Indolent and Aggressive Lymphomas
mTOR Inhibition in Aggressive Lymphomas
Immunomodulatory Agents in Aggressive Lymphomas
Summary

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.